Molnarz 200 mg Capsule

Molnarz 200 mg Capsule

S4
PDF Leaflet Revision Date: 25 July 2023

API: Molnupiravir | Company: Aurogen Sa

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of mild to moderate COVID-19 in adults at risk for severe illness.

Dosage (summary)

800 mg (four 200 mg capsules) orally every 12 hours for 5 days.

Onset of Action / Duration

Onset: within 5 days of symptom onset, Duration: 5 days.

Special Populations

  • Elderly
  • Renal impairment
  • Hepatic impairment

Pregnancy & Breastfeeding

Not recommended during pregnancy; breastfeeding not recommended during treatment and for 4 days after.

Contraindications

  • Hypersensitivity to molnupiravir or excipients

Common side effects

  • Diarrhoea
  • Nausea
  • Dizziness

Counselling Points

  • Take with or without food
  • Do not double dose if missed
  • Use contraception during treatment and for 4 days after
Important Disclaimer

The Molnarz 200 mg Capsule professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites